A New Look at Peripheral Tolerance, or, Good Genes Behaving Badly

owner image
National Institutes of Health
Wednesday, March 14, 2012 | 3pm EDT (US and Canada) / March 15, 3am CST (China) / 7pm GMT (UK) Long > 60 min | English

Webinar Details

Description: Understanding the pathogenesis of T1D should facilitate the development of novel disease biomarkers and therapeutics that can accomplish a stated goal of NIDDK, to block T1D progression before complete  cell destruction. The major emphasis placed on disease associated genetic mutations or polymorphisms to understand the genetics of T1D has failed to advance either understanding of T1D pathogenesis or to identify therapeutic targets. Recent studies from the Fathman lab have demonstrated that tissue- and disease-specific changes in mRNA expression, rather than DNA variants, may underlie the progression of T1D. Work to be presented emphasizes the importance of studying the control of tissue-specific gene expression in relationship to the pathogenesis of T1D. By combining their expertise in T1D research with their established preclinical models and patient samples/tissues from their collaborator, the Network for Pancreatic Organ Donors with Diabetes, nPOD http://www.jdrfnpod.org, Fathman and colleagues have both demonstrated a potential defect in peripheral tolerance in NOD mice that has homologies in T1D patients and have demonstrated that appropriate immunotherapy may overcome this defect

More Information

Webinar Type: Recorded


C. G. (Garry) Fathman
C. G. (Garry) Fathman
Dr. C. Garrison Fathman is Professor of Medicine and Chief of the Division of Immunology and Rheumatology at Stanford University School of Medicine and Associate Director of the Institute for Immunology, Transplantation and Infection (ITI) and Director of the Center for Clinical Immunology at Stanford (CCIS). He was Founder and first-President of the Federation of Clinical Immunology Societies (FOCIS). His substantial scientific contributions in the areas of cellular and molecular immunology have brought him international recognition. As Director of the CCIS, Dr. Fathman has initiated a multidisciplinary approach to study and treat autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and insulin-dependent diabetes mellitus, and has initiated several new approaches to education and community outreach. Dr. Fathman received his undergraduate degree from the University of Kentucky in 1964 and his M.D. from Washington University in St. Louis in 1969. He subsequently completed his residency training at Dartmouth Affiliated Hospitals and completed a fellowship in immunology and rheumatology at Stanford University. Dr. Fathman then spent four years doing research, first as a clinical associate at the National Cancer Institute of the NIH, and then as a member of the Basel Institute of Immunology in Switzerland. He returned to the United States to join the faculty at the Mayo Clinic Medical School in 1977 and was recruited back to Stanford University in 1981. Dr. Fathman is a member of many professional organizations, including the American Association of Immunologists (AAI) and the Association of American Physicians (AAP), and is past council member of the American Society for Clinical Investigation (ASCI) and past-President of the Clinical Immunology Society (CIS). He was Associate Editor of the Annual Review of Immunology for 25 years and serves on the editorial boards of numerous scientific journals. Dr. Fathman has chaired a variety of national and international professional meetings, served on NIH study sections and numerous blue ribbon panels and has written more than 250 articles on his research.

Related Webinars